Lupin

Mumbai, India Founded: 1968 • Age: 58 yrs Listed Fortune India 500 · #121
Pharmaceutical products including generics, biosimilars, and APIs are manufactured.
Request Access
Report Incorrect Data
Page last updated

About Lupin

Lupin is a publicly listed company based in Mumbai (India) founded in 1968. Pharmaceutical products including generics, biosimilars, and APIs are manufactured. The company has 26,210 employees. Lupin has completed 11 acquisitions, including Biocom, Biocom California and Harmosan Pharma. Its chief executive, as recorded, is Vinita D Gupta. Its website lupin.com draws about 216 thousand monthly visits. Its Indian entity Lupin Limited reported revenue of ₹29,039 Cr. Its focus areas include Diversified Pharmaceuticals and Drugs.

Company details

Lupin was founded in 1968 in Mumbai, India, within the pharmaceutical sector. Generics, biosimilars, and active pharmaceutical ingredients are produced, alongside offerings in key therapeutic areas. Tech-driven solutions, over-the-counter medications, biotech products, and contract development and manufacturing organization services are provided. A global institutional business is operated, with manufacturing solutions extended internationally. Research and development efforts are directed toward advancing industry standing.

Lupin is ranked #121 on the Fortune India 500 (2025).

Recognitions & Rankings of Lupin

Fortune India 500 2025 edition
Rank#121
Total income
₹23,167 Cr
Profit
₹3,282 Cr
Last year #120
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#72
Valuation
₹96,050 Cr
2023 #89 2022 #130 2021 #96
  • Headquarters Mumbai, India
  • Employees 26,210
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website lupin.com
  • Social LinkedIn X Facebook
  • Legal Name Lupin Limited
Operational Areas
Healthcare → Pharmaceuticals & Distribution
Key Metrics
  • Market Cap
    ₹88,207 Cr

    LUPIN · NSE

  • Share Price
    ₹1,959.90

    +1.61% today

  • Revenue
    ₹27,958 Cr

    FY 2025-26 · +23.1% YoY

  • EBITDA
    ₹7,602 Cr

    Margin 27.2%

  • Net Profit
    ₹5,688 Cr

    FY 2025-26 · +76.4% YoY

  • P/E (TTM)
    15.1x

    P/B 4.0x

  • ROE
    27.0%

    ROCE 27.4%

  • Debt / Equity
    0.30

    Interest cover 7.0x

  • Latest Funding Round
    $25M (USD), Post-IPO

    Jun 2023

  • Investors
    AbbVie

    & 2 more

  • Employee Count
    26,210
  • Investments & Acquisitions
    Biocom

    & 10 more

Funding Insights of Lupin

  • Total Rounds 5
  • Last Round Post-IPO — $25M
  • First Round $150,000

    (Jul 2013)

  • Investors Count 3

All 5 funding rounds of Lupin with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2023$25MPost-IPO––
AbbVie
May 2021$50MPost-IPO––
Boehringer Ingelheim
Dec 2016$220,014Grant––
National Science Foundation
Sep 2013Post-IPO––
–
Jul 2013$150,000Grant––
National Science Foundation
Valuation history

3 investors in total: 3 institutional.

Investors in Lupin

Lupin has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include AbbVie, Boehringer Ingelheim and National Science Foundation.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
AbbVie
Biopharmaceutical research and drug development are conducted globally by AbbVie.
2012abbvie.comChicago, United States
Boehringer Ingelheim
Generic drugs and clinical research services are provided globally.
1885boehringer-ingelheim.com
National Science Foundation
A government-backed foundation providing seed-stage investments to support small businesses.
1950nsf.govArlington, United States
Premium access

Investor details for Lupin

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Lupin Limited (Lupin)

Lupin Limited is the primary company behind Lupin. The board of Lupin Limited currently have 10 directors; the longest-serving is Vinita Deshbandhu Gupta, appointed in 2001. 21 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Vinita Deshbandhu Gupta
DIN 00058631
Whole-time director17 Aug 200125 yrs 2 moLupin Limited
Nilesh Deshbandhu Gupta
DIN 01734642
Managing Director01 Sep 201313 yrs 1 moLupin Limited
Manju Deshbandhu Gupta
DIN 00209461
Director01 Apr 201412 yrs 6 moLupin Limited
Ramesh Swaminathan
DIN 01833346
Whole-time director26 Mar 20206 yrs 7 moLupin Limited
Kanwar Bir Singh Anand
DIN 03518282
Director12 Aug 20206 yrs 2 moLupin Limited
Mark Daniel Mc Dade
DIN 09037255
Director28 Jan 20215 yrs 8 moLupin Limited
Jeffrey Bruce Kindler
DIN 10592395
Director06 May 20242 yrs 5 moLupin Limited
Alfonso Martin Gimenez Zulueta
DIN 10597962
Director06 May 20242 yrs 5 moLupin Limited
Punita Lal
DIN 03412604
Director14 May 20251 yr 5 moLupin Limited
Anand Kripalu
DIN 00118324
Director01 Feb 20268 moLupin Limited

People of Lupin

362 people are tracked at Lupin (129 in leadership, 6 in board & advisors, 227 in team); the tracked headcount is 26,210.

NameRoleGroup
Vinita D Gupta
CEOLeadership
Abdelaziz Toumi
CEOLeadership
Nilesh D Gupta
Managing DirectorLeadership
Narendra K Saini
CDO | Chief Digital & Data OfficerLeadership
Nandan Singh
Deputy General Manager - Human ResourcesLeadership
Raghu V Kolluri Ph.d.
Global Head - Investigations & CQA ITLeadership
Girish Vyas
Deputy General Manager Of FinanceLeadership
Vinita Gupta
CEOLeadership
Yashwant Mahadik
President, Global Human ResourcesLeadership
Sunil Makharia
President, FinanceLeadership
Thierry Volle
President, Europe, Middle-East & AfricaLeadership
Fabrice Egros
President, Global Corporate Development & Growth MarketsLeadership
Ramesh Swaminathan
Executive Director, Global CFO & Head, Corporate AffairsLeadership
Spiro Gavaris
President, US GenericsLeadership
Shahin Fesharaki
President, Global Chief Scientific OfficerLeadership
Tushara Shankar
Sr. Gm/ Head- Corporate Social ResponsibilityLeadership
Kiritkumar Dumraliya
Deputy General Manager – Strategic IT Projects (cio Office)Leadership
Ruth Blättler-Egli
Associate Director / HR Lead EMEALeadership
Rishabh Deo Mall
Deputy GM - Head Of Data Science And AnalyticsLeadership
Sanjay Rahurkar
Head HR - Baroda PlantLeadership

342 more people are available in the full profile.

Premium access

Complete people profiles for Lupin

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Lupin

Lupin is a publicly listed company on the NSE with ticker symbol LUPIN in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date10 Sep 2001
  • Listed onNSE: LUPIN
  • Listed entityLupin Limited
  • Exchange sectorHealth technology
  • ISININE326A01037
  • Share price₹1,953.20 (-0.02% on the day) · 2026-10-14
  • Market capitalisation₹89,629 Cr
  • Price to earnings16.2
  • EPS (diluted, trailing year)₹120.73
  • Dividend yield0.92%
  • Volume (last session)795,302

Financials of Lupin

Exchange-reported figures of Lupin Limited, the listed company behind Lupin (NSE: LUPIN).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹27,958 Cr
+23.1% YoY
EBITDA
₹7,602 Cr
+44.0% YoY
Profit After Tax
₹5,688 Cr
+76.4% YoY
Net Worth
₹22,448 Cr
+30.5% YoY
Total Assets
₹29,973 Cr
+27.9% YoY
Total Debt
₹6,616 Cr
+21.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue27,95822,70820,01116,64216,40515,16315,375
Revenue growth+23.1%+13.5%+20.3%+1.4%+8.2%-1.4%-
EBITDA7,6025,2783,8001,7212192,5671,603
EBITDA margin+27.2%+23.2%+19.0%+10.3%+1.3%+16.9%+10.4%
Profit before tax6,8734,0152,422716(1,372)1,676887
Net profit5,6883,2251,892410(1,561)1,177(470)
Net profit margin+20.3%+14.2%+9.5%+2.5%-9.5%+7.8%-3.1%
EPS (₹)116.6471.8742.019.45(33.62)26.81(5.95)
Balance sheet
Total assets29,97323,43418,01617,78917,09919,71120,071
Net worth22,44817,20414,29012,46412,15313,80312,537
Total debt6,6165,4482,9224,5424,1584,7836,305
Cash & bank5,6533,1421,2031,2931,0981,7422,454
Net working capital12,27710,1956,8667,0747,1537,9408,362
Cash flow
Cash from operations7,3343,0003,6481,8973671,8221,469
Cash from investing(3,865)(4,172)(1,712)(1,287)1,292(1,240)1,107
Cash from financing(846)1,732(2,184)(337)(1,572)(1,885)(891)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue8,2777,4757,1687,0486,2685,6675,7685,673
Revenue growth (YoY)+32.0%+31.9%+24.3%+24.2%+11.9%---
Other income13014111590.0079.0456.9553.7142.29
EBITDA2,4502,3541,8352,3411,7271,3211,3561,340
EBITDA margin+29.8%+31.8%+25.8%+34.3%+28.0%+23.8%+24.1%+24.4%
Depreciation453447313317299393271257
Interest11012011510891.7689.1066.8970.87
Profit before tax2,0171,9281,5222,0071,4168961,0711,055
Tax600459342522194113212195
Net profit1,4171,4691,1811,4851,221782859859
EPS (₹)30.8934.7525.6732.2826.6216.8718.6918.64
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue19,51316,96814,66611,25911,77211,05611,026
Revenue growth+15.0%+15.7%+30.3%-4.4%+6.5%+0.3%-
EBITDA7,1765,3163,4509642092,0441,148
EBITDA margin+36.8%+31.3%+23.5%+8.6%+1.8%+18.5%+10.4%
Profit before tax7,6944,8372,785527(162)1,6301,052
Net profit5,7744,0002,302411(219)1,2171,153
Net profit margin+29.6%+23.6%+15.7%+3.7%-1.9%+11.0%+10.5%
EPS (₹)139.2587.0151.049.35(4.15)27.7416.06
Balance sheet
Total assets31,87325,03721,13519,55419,43919,40917,937
Net worth30,13424,27820,60318,41218,15018,56617,473
Total debt1,1152501057499514855.83
Cash & bank12845913910164.562841,306
Net working capital8,0627,6514,8474,1874,9285,0645,959
Cash flow
Cash from operations5,5402,4452,5041,7941511,5702,219
Cash from investing(5,649)(1,766)(1,599)(1,269)(372)(2,508)(740)
Cash from financing(121)(460)(867)(498)102(53.17)(368)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue7,1725,2354,5014,0685,7094,4864,2084,106
Revenue growth (YoY)+25.6%+16.7%+7.0%-0.9%+37.0%---
Other income10253799.8066354.1448.7955.3032.62
Total expenses3,4392,9533,5182,8932,9792,7402,8742,991
EBITDA3,7332,2829831,1762,7301,7461,3341,115
EBITDA margin+52.5%+44.3%+22.2%+30.5%+48.7%+39.8%+32.9%+28.4%
Depreciation190177179175177208153146
Interest35.5638.7736.0227.7818.9033.8519.5517.55
Profit before tax3,6102,6028681,6362,5881,5531,217984
Tax895439150278460262232176

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 26 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue8,2777,4757,1687,0486,2685,6675,7685,673
Revenue growth (YoY)+32.0%+31.9%+24.3%+24.2%+11.9%---
Other income13014111590.0079.0456.9553.7142.29
EBITDA2,4502,3541,8352,3411,7271,3211,3561,340
EBITDA margin+29.8%+31.8%+25.8%+34.3%+28.0%+23.8%+24.1%+24.4%
Depreciation453447313317299393271257
Interest11012011510891.7689.1066.8970.87
Profit before tax2,0171,9281,5222,0071,4168961,0711,055
Tax600459342522194113212195
Net profit1,4171,4691,1811,4851,221782859859
EPS (₹)30.8934.7525.6732.2826.6216.8718.6918.64
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue27,95822,70820,01116,64216,40515,16315,375
Revenue growth+23.1%+13.5%+20.3%+1.4%+8.2%-1.4%-
Other income1,081202131151210138618
Total expenses20,35617,43016,21114,92116,18712,59613,772
Employee cost4,5753,9643,4953,0872,9892,8262,987
EBITDA7,6025,2783,8001,7212192,5671,603
EBITDA margin+27.2%+23.2%+19.0%+10.3%+1.3%+16.9%+10.4%
Depreciation1,3761,1691,1978811,659887970
Interest434295312274143141363
Profit before tax6,8734,0152,422716(1,372)1,676887
Tax1,5177094872691374491,157
Net profit5,6883,2251,892410(1,561)1,177(470)
Net profit margin+20.3%+14.2%+9.5%+2.5%-9.5%+7.8%-3.1%
EPS (₹)116.6471.8742.019.45(33.62)26.81(5.95)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital91.4491.3291.1491.0090.9090.7490.60
Reserves & surplus22,35717,11214,19912,37412,06213,71212,446
Shareholders' funds (net worth)22,44817,20414,29012,46412,15313,80312,537
Minority interest65.1090.8583.1678.3268.7154.9744.46
Secured loans2,6602,3960.000.00142243176
Unsecured loans3,9563,0522,9224,5424,0174,5406,130
Total debt6,6165,4482,9224,5424,1584,7836,305
Total liabilities29,97323,43418,01617,78917,09919,71120,071
Assets
Gross block23,21720,18419,66518,07715,99014,72714,160
Net block10,9949,7198,8788,3557,3827,8817,938
Capital work in progress1,0165177731,2381,1461,066940
Investments3,6701,1461,0755179002,4552,374
Inventories6,0835,4764,9544,4924,6314,0923,457
Sundry debtors6,6045,4974,6924,4814,2624,4745,446
Cash & bank balances5,6533,1421,2031,2931,0981,7422,454
Loans & advances2,1101,6241,7521,7461,6441,3011,718
Total current assets20,45015,73912,60112,01211,63511,61013,075
Total current liabilities8,1735,5445,7354,9384,4823,6694,713
Net working capital12,27710,1956,8667,0747,1537,9408,362
Total assets29,97323,43418,01617,78917,09919,71120,071
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash1,5449841,2329919262,229544
Net cash from operating activities7,3343,0003,6481,8973671,8221,469
Net cash from investing activities(3,865)(4,172)(1,712)(1,287)1,292(1,240)1,107
Net cash from financing activities(846)1,732(2,184)(337)(1,572)(1,885)(891)
Net change in cash2,624560(248)27387.22(1,303)1,685
Closing cash5,6533,1421,2031,2931,0981,7422,454
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+23.1%+13.5%+20.3%+1.4%+8.2%-1.4%-
EBITDA growth+44.0%+38.9%+120.9%+686.3%-91.5%+60.2%-
PBT growth+71.2%+65.8%+238.1%+9998.0%-+88.9%-41.0%
Net income growth+76.4%+70.5%+361.8%+126.2%-232.6%+350.3%-
Revenue CAGR (3Y)+18.9%+11.5%+9.7%+2.7%+3.8%-1.4%-4.0%
EBITDA CAGR (3Y)+64.1%+188.9%+14.0%+2.4%-53.8%+15.1%-29.1%
Profitability & leverage
Net income margin+19.2%+14.6%+9.7%+2.7%-9.2%+8.1%-1.8%
Return on capital employed+27.4%+20.9%+15.3%+5.7%-6.7%+9.2%+8.1%
Return on net worth+27.0%+21.0%+14.5%+3.6%-11.6%+9.3%-3.6%
Debt / equity0.300.270.280.350.340.420.56
Long-term debt / equity0.110.070.010.010.010.070.32
Interest cover6.987.1811.9732.66-9.928.3757.39
Efficiency & per share
Fixed asset turnover1.291.141.060.981.071.051.03
Inventory turnover4.844.354.243.653.764.024.22
Debtors turnover4.624.464.363.813.763.062.90
EPS (₹)116.6471.8742.019.45(33.62)26.81(5.95)
Dividend per share (₹)18.0012.008.004.004.006.506.00
Book value per share (₹)490.99376.77313.59273.95267.40304.23276.75
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue7,1725,2354,5014,0685,7094,4864,2084,106
Revenue growth (YoY)+25.6%+16.7%+7.0%-0.9%+37.0%---
Other income10253799.8066354.1448.7955.3032.62
Total expenses3,4392,9533,5182,8932,9792,7402,8742,991
EBITDA3,7332,2829831,1762,7301,7461,3341,115
EBITDA margin+52.5%+44.3%+22.2%+30.5%+48.7%+39.8%+32.9%+28.4%
Depreciation190177179175177208153146
Interest35.5638.7736.0227.7818.9033.8519.5517.55
Profit before tax3,6102,6028681,6362,5881,5531,217984
Tax895439150278460262232176
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue19,51316,96814,66611,25911,77211,05611,026
Revenue growth+15.0%+15.7%+30.3%-4.4%+6.5%+0.3%-
Other income1,346253116210217129475
Total expenses12,33611,65211,21610,29511,5639,0129,877
Employee cost2,5452,3122,0961,9341,9181,6961,703
EBITDA7,1765,3163,4509642092,0441,148
EBITDA margin+36.8%+31.3%+23.5%+8.6%+1.8%+18.5%+10.4%
Depreciation707648725548514503519
Interest12184.5056.3598.4473.4740.6252.59
Profit before tax7,6944,8372,785527(162)1,6301,052
Tax1,32886445910227.17371325
Net profit5,7744,0002,302411(219)1,2171,153
Net profit margin+29.6%+23.6%+15.7%+3.7%-1.9%+11.0%+10.5%
EPS (₹)139.2587.0151.049.35(4.15)27.7416.06
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital91.4491.3291.1491.0090.9090.7490.60
Reserves & surplus30,04224,18720,51218,32118,05918,47517,383
Shareholders' funds (net worth)30,13424,27820,60318,41218,15018,56617,473
Secured loans0.000.000.000.000.0050.795.29
Unsecured loans1,1152501057499514350.54
Total debt1,1152501057499514855.83
Total liabilities31,87325,03721,13519,55419,43919,40917,937
Assets
Gross block9,0448,6737,6057,4086,7056,2305,666
Net block4,8734,9464,1134,0223,6903,6393,514
Capital work in progress523278446927947951822
Investments15,62511,95511,5819,9749,5119,5637,456
Inventories3,3513,2272,9693,0193,1772,7082,485
Sundry debtors6,9225,6643,8422,6742,7223,1913,616
Cash & bank balances12845913910164.562841,306
Loans & advances1,7691,5411,5291,3361,6521,1141,102
Total current assets12,17010,8918,4797,1317,6157,2968,509
Total current liabilities4,1083,2403,6322,9442,6872,2332,550
Net working capital8,0627,6514,8474,1874,9285,0645,959
Total assets31,87325,03721,13519,55419,43919,40917,937
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash34212485.6659.101771,16855.94
Net cash from operating activities5,5402,4452,5041,7941511,5702,219
Net cash from investing activities(5,649)(1,766)(1,599)(1,269)(372)(2,508)(740)
Net cash from financing activities(121)(460)(867)(498)102(53.17)(368)
Net change in cash(230)21838.0426.56(118)(991)1,112
Closing cash12845913910164.562841,306
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+15.0%+15.7%+30.3%-4.4%+6.5%+0.3%-
EBITDA growth+35.0%+54.1%+258.0%+360.9%-89.8%+78.0%-
PBT growth+59.1%+73.7%+428.3%+9998.0%-+54.9%-55.1%
Net income growth+44.3%+73.8%+460.5%+287.3%-118.0%+5.5%-
Revenue CAGR (3Y)+20.1%+13.0%+9.9%+0.7%+1.2%+3.1%-4.4%
EBITDA CAGR (3Y)+95.3%+194.0%+19.1%-5.7%-56.3%-0.7%-36.5%
Profitability & leverage
Net income margin+32.6%+23.4%+15.9%+3.8%-1.6%+11.4%+6.6%
Return on capital employed+27.5%+21.3%+14.0%+3.2%-0.6%+9.0%+10.0%
Return on net worth+23.4%+17.7%+11.9%+2.3%-1.2%+7.0%+6.7%
Debt / equity0.030.010.020.050.040.010.00
Long-term debt / equity0.010.010.000.000.010.000.00
Interest cover1.881.812.0723.69-24.082.648.35
Efficiency & per share
Fixed asset turnover2.202.081.951.601.821.862.11
Inventory turnover5.935.484.903.634.004.264.60
Debtors turnover3.103.574.504.173.983.253.00
EPS (₹)139.2587.0151.049.35(4.15)27.7416.06
Dividend per share (₹)18.0012.008.004.004.006.506.00
Book value per share (₹)659.09531.72452.12404.66399.34409.20385.72

Investments & Acquisitions by Lupin

Lupin has strategically engaged in corporate development activities, having acquired 11 companies. Notable acquisitions include Biocom, Biocom California and Harmosan Pharma.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
VISUfarma
Ophthalmic medicine products are manufactured by VISUfarma in Amsterdam.
visufarma.comAmsterdam, Netherlands2016Sep 2025••••
Renasciencepharma
Critical care pharmaceuticals are manufactured to revive forgotten medicines.
renasciencepharma.com0Apr 2025$15.89M
Southern Cross Pharma
Pharmaceutical products and generic drugs are manufactured.
southernxp.comHawthorn, Australia2000Jul 2021••••
Symbiomix Therapeutics
Late-stage biopharma antibiotics for gynecological infections are developed.
symbiomix.comNewark, United States2012Oct 2017$150M
Biocom California
Drug discovery and development are provided for multiple therapeutic areas.
biocom.orgSan Diego, United States1995Jul 2015••••
Biocom
Lubricant data and software solutions are provided for the industry.
biocom.ruStavropol, Russia1991Jul 2015••••
Laboratorios Grin
Manufacturer of high-quality ophthalmic medications and solutions
laboratoriosgrin.comMexico1955Mar 2014••••
Nanomi
Sustained release injectables are developed and manufactured using Monosphere Technology.
nanomi.comOldenzaal, Netherlands2004Feb 2014••••
Multicare
Domain name escrow and registration services are facilitated securely.
multicare.com.phManila, Philippines2002Mar 2009••••
Harmosan Pharma
Electricity is generated and natural gas processing services are provided.
hormosan.comFrankfurt Am Main, Germany1968Jul 2008••••
Premium access

Complete acquisition details for Lupin

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Lupin

14 dated milestones of Lupin across 57 years, from founding to its latest funding, stage changes and deals.

  1. Founded Lupin is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Acquisition Acquires Harmosan Pharma.
  4. Acquisition Acquires Multicare.
  5. Funding First funding round of $150K.
  6. Acquisition Acquires Nanomi.
  7. Acquisition Acquires Laboratorios Grin.
  8. Acquisition Acquires Biocom California.
  9. Acquisition Acquires Biocom.
  10. Acquisition Acquires Symbiomix Therapeutics.
  11. Acquisition Acquires Southern Cross Pharma.
  12. Funding Latest funding round, Post-IPO, of $25.0M.
  13. Acquisition Acquires Renasciencepharma.
  14. Acquisition Acquires VISUfarma.

Web traffic of Lupin

The website of Lupin (lupin.com) receives about 216.4K visits a month and ranks #208,025 among all websites worldwide, #133 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    216.4K

    ▲ 72.1% vs previous month

  • Unique visitors
    38.4K

    per month

  • Global rank
    #208,025

    among all websites

  • Category rank
    #133

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Lupin. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
lupinworld.com
lupinworld.com
100%
–
Ajanta Pharma
ajantapharma.com
83%
20.1K#1,412,069View details
Natco Pharma
natcopharma.co.in
77%
19.8K#1,133,324View details
Express Pharma
expresspharma.in
76%
#475,093View details
Alembic Pharmaceuticals
alembicpharmaceuticals.com
71%
23K#2,083,600View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 40 similar websites and full traffic analytics for Lupin

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Lupin

Lupin: USFDA Inspection Finds One Observation At Goa Plant, Co Promises To Fix It And Stay Compliant.
Exchange Update • 2 days ago
Lupin: Co Names Brian Savage As New President And Chief Legal Officer, Formerly Worked As EVP And Interim Global CLO At Teva Pharmaceuticals.
Exchange Update • 3 days ago
Lupin Receives U.S. FDA Approval for Phytonadione Injectable Emulsion USP
PR Newswire • 17 days ago
Lupin: Company Gets US FDA Nod for Phytonadione Injectable Emulsion 1 MG/0.5 ML Pre-filled Syringe.
Exchange Update • 18 days ago
Lupin Launches World's First Triple Combination Drug for COPD in India
Udaipur Kiran • 20 days ago
Lupin launches fixed-dose triple combination inhaler for COPD in India - The Economic Times
Economic Times • 20 days ago
Lupin: Launches Formoflo-g MDI, World’s First Fixed-dose Triple Combination Drug For COPD Management
Exchange Update • 20 days ago
Lupin receives tentative U.S. FDA approval for Apixaban Oral Suspension
The Hindu • 28 days ago
Lupin: Co. Receives Tentative Approval From U.s. FDA For Novel Apixaban Oral Suspension
Exchange Update • 28 days ago
Lupin: HSBC on Lupin Maintains Buy with Target Price of ₹2,500 as the current valuation overemphasises known concentration risks while underappreciating the US launch pipeline, with new launches expected to sustain ~US$1.2bn US sales during FY27–29E and continued traction across India and other ex-US segments.
Exchange Update • 1 month ago
Premium access

Complete news archive for Lupin

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Articles about Lupin on our blog

Frequently Asked Questions about Lupin

Lupin was founded in 1968 and raised its 1st funding round 45 years after it was founded.

Lupin is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Vinita D Gupta is the CEO of Lupin, as recorded in our data.

Lupin has 26,210 employees.

The primary company behind Lupin, Lupin Limited, reported revenue of ₹29,039 Cr for FY 2026, up 23% year on year.

Lupin was founded in 1968 in Mumbai, India, within the pharmaceutical sector. Generics, biosimilars, and active pharmaceutical ingredients are produced, alongside offerings in key therapeutic areas. Tech-driven solutions, over-the-counter medications, biotech products, and contract development and manufacturing organization services are provided. A global institutional business is operated, with manufacturing solutions extended internationally. Research and development efforts are directed toward advancing industry standing.

Yes, Lupin is publicly traded on NSE under the ticker symbol LUPIN.

Lupin has made 11 acquisitions, including Biocom, Biocom California, and Harmosan Pharma.

Lupin has 3 investors. Key investors include AbbVie, Boehringer Ingelheim, and National Science Foundation.

Lupin operates through Lupin Limited.

The legal entities of Lupin currently have 11 directors, including Vinita Deshbandhu Gupta, Ramesh Swaminathan, Nilesh Deshbandhu Gupta and others.

The website of Lupin receives about 216 thousand visits a month and ranks #208,025 among all websites worldwide.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available